Aldeyra Therapeutics, Inc. — All Filings
621 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
144
3
4
4/A
424B1
424B4
424B5
8-A12B
8-A12B/A
8-K
8-K/A
ARS
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DRS
DRS/A
EFFECT
FWP
POS AM
REGDEX
S-1
S-1/A
S-3
S-8
S-8 POS
SC 13G
SC 13G/A
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | 8-K | 0001193125-24-231158 | Oct 2, 2024 | Sep 30, 2024 |
| 3 | 3 | 0000950170-24-105145 | Sep 10, 2024 | Aug 31, 2024 |
| 8-K | 8-K | 0001193125-24-211645 | Sep 3, 2024 | Aug 29, 2024 |
| 4 | 4 | 0000950170-24-097070 | Aug 14, 2024 | Aug 12, 2024 |
| 4 | 4 | 0000950170-24-097071 | Aug 14, 2024 | Aug 12, 2024 |
| 144 | — | 0001928391-24-000002 | Aug 12, 2024 | — |
| 144 | — | 0001928391-24-000001 | Aug 12, 2024 | — |
| 8-K | CURRENT REPORT | 0001213900-24-066327 | Aug 8, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-089238 | Aug 1, 2024 | Jun 30, 2024 |
| 8-K | 8-K | 0001193125-24-191518 | Aug 1, 2024 | — |
| 424B5 | 424B5 | 0001193125-24-191601 | Aug 1, 2024 | — |
| 8-K | CURRENT REPORT | 0001213900-24-054003 | Jun 20, 2024 | — |
| 8-K | CURRENT REPORT | 0001213900-24-052234 | Jun 13, 2024 | — |
| 8-K | 8-K | 0001193125-24-157328 | Jun 7, 2024 | Jun 4, 2024 |
| 4 | 4 | 0000950170-24-069900 | Jun 6, 2024 | Jun 4, 2024 |
| 4 | 4 | 0000950170-24-069890 | Jun 6, 2024 | Jun 4, 2024 |
| 4 | 4 | 0000950170-24-069874 | Jun 6, 2024 | Jun 4, 2024 |
| 4 | 4 | 0000950170-24-069885 | Jun 6, 2024 | Jun 4, 2024 |
| 4 | 4 | 0000950170-24-069887 | Jun 6, 2024 | Jun 4, 2024 |
| 4 | 4 | 0000950170-24-069888 | Jun 6, 2024 | Jun 4, 2024 |
| 10-Q | 10-Q | 0000950170-24-052056 | May 2, 2024 | Mar 31, 2024 |
| 8-K | CURRENT REPORT | 0001213900-24-035953 | Apr 25, 2024 | — |
| EFFECT | — | 9999999995-24-001104 | Apr 24, 2024 | — |
| DEF 14A | DEF 14A | 0001193125-24-104862 | Apr 22, 2024 | Jun 4, 2024 |
| DEFA14A | DEFA14A | 0001193125-24-104866 | Apr 22, 2024 | — |
| ARS | ARS | 0001193125-24-104887 | Apr 22, 2024 | Dec 31, 2023 |
| CORRESP | — | 0001193125-24-104917 | Apr 22, 2024 | — |
| 4/A | 4/A | 0000950170-24-045108 | Apr 17, 2024 | Mar 11, 2024 |
| 4/A | 4/A | 0000950170-24-045113 | Apr 17, 2024 | Mar 12, 2024 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-24-008171 | Apr 8, 2024 | Apr 4, 2024 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-24-007959 | Apr 3, 2024 | Apr 1, 2024 |
| 8-K | CURRENT REPORT | 0001213900-24-026871 | Mar 28, 2024 | — |
| UPLOAD | — | 0000000000-24-002751 | Mar 13, 2024 | — |
| 4 | 4 | 0000950170-24-030311 | Mar 12, 2024 | Mar 9, 2024 |
| 4 | 4 | 0000950170-24-030314 | Mar 12, 2024 | Mar 9, 2024 |
| 4 | 4 | 0000950170-24-030309 | Mar 12, 2024 | Mar 9, 2024 |
| 144 | — | 0001950047-24-002180 | Mar 12, 2024 | — |
| 144 | — | 0001836354-24-000002 | Mar 11, 2024 | — |
| 144 | — | 0001972362-24-000397 | Mar 11, 2024 | — |
| 144 | — | 0001836354-24-000001 | Mar 11, 2024 | — |
| 10-K | 10-K | 0000950170-24-027933 | Mar 7, 2024 | Dec 31, 2023 |
| S-8 POS | S-8 POS | 0001193125-24-062265 | Mar 7, 2024 | — |
| S-8 | S-8 | 0001193125-24-062277 | Mar 7, 2024 | — |
| S-3 | S-3 | 0001193125-24-062285 | Mar 7, 2024 | — |
| SC 13G/A | SC 13G/A | 0001193125-24-036469 | Feb 14, 2024 | — |
| 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 0001157523-24-000230 | Feb 13, 2024 | — |
| SC 13G | SCHEDULE 13G | 0001104659-24-020218 | Feb 13, 2024 | — |
| SC 13G | — | 0001086364-24-005555 | Jan 29, 2024 | — |
| 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 0001157523-24-000014 | Jan 4, 2024 | — |
| 8-K | 8-K | 0001193125-23-301185 | Dec 21, 2023 | — |